Viatris Price to Book Ratio 2012-2026 | VTRS
Historical price to book ratio values for Viatris (VTRS) over the last 10 years. The current price to book ratio for Viatris as of September 16, 2026 is 1.39.
| Viatris Price/Book Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | Book Value per Share | Price to Book Ratio |
| 2026-09-16 | 17.02 | 1.38 | |
| 2026-06-30 | 15.76 | $12.34 | 1.28 |
| 2026-03-31 | 13.31 | $12.59 | 1.06 |
| 2025-12-31 | 12.16 | $12.78 | 0.95 |
| 2025-09-30 | 9.56 | $13.13 | 0.73 |
| 2025-06-30 | 8.53 | $13.36 | 0.64 |
| 2025-03-31 | 8.20 | $13.20 | 0.62 |
| 2024-12-31 | 11.58 | $15.61 | 0.74 |
| 2024-09-30 | 10.70 | $16.58 | 0.65 |
| 2024-06-30 | 9.69 | $16.36 | 0.59 |
| 2024-03-31 | 10.77 | $16.81 | 0.64 |
| 2023-12-31 | 9.67 | $17.05 | 0.57 |
| 2023-09-30 | 8.69 | $17.39 | 0.50 |
| 2023-06-30 | 8.70 | $17.38 | 0.50 |
| 2023-03-31 | 8.28 | $17.45 | 0.47 |
| 2022-12-31 | 9.48 | $17.36 | 0.55 |
| 2022-09-30 | 7.18 | $15.82 | 0.45 |
| 2022-06-30 | 8.72 | $16.34 | 0.53 |
| 2022-03-31 | 8.97 | $16.87 | 0.53 |
| 2021-12-31 | 11.06 | $16.94 | 0.65 |
| 2021-09-30 | 10.98 | $17.48 | 0.63 |
| 2021-06-30 | 11.49 | $17.54 | 0.66 |
| 2021-03-31 | 11.16 | $17.72 | 0.63 |
| 2020-12-31 | 14.97 | $19.02 | 0.79 |
| 2020-09-30 | 11.84 | $24.27 | 0.49 |
| 2020-06-30 | 12.84 | $22.72 | 0.57 |
| 2020-03-31 | 11.91 | $21.79 | 0.55 |
| 2019-12-31 | 16.05 | $23.02 | 0.70 |
| 2019-09-30 | 15.80 | $22.21 | 0.71 |
| 2019-06-30 | 15.21 | $23.07 | 0.66 |
| 2019-03-31 | 22.63 | $23.03 | 0.98 |
| 2018-12-31 | 21.88 | $23.59 | 0.93 |
| 2018-09-30 | 29.23 | $23.40 | 1.25 |
| 2018-06-30 | 28.86 | $23.68 | 1.22 |
| 2018-03-31 | 32.88 | $25.57 | 1.29 |
| 2017-12-31 | 33.79 | $25.39 | 1.33 |
| 2017-09-30 | 25.05 | $24.78 | 1.01 |
| 2017-06-30 | 31.00 | $23.94 | 1.30 |
| 2017-03-31 | 31.14 | $21.75 | 1.43 |
| 2016-12-31 | 30.47 | $20.77 | 1.47 |
| 2016-09-30 | 30.44 | $22.11 | 1.38 |
| 2016-06-30 | 34.53 | $20.32 | 1.70 |
| 2016-03-31 | 37.01 | $20.91 | 1.77 |
| 2015-12-31 | 43.18 | $19.91 | 2.17 |
| 2015-09-30 | 32.15 | $19.96 | 1.61 |
| 2015-06-30 | 54.19 | $19.47 | 2.78 |
| 2015-03-31 | 47.40 | $18.58 | 2.55 |
| 2014-12-31 | 45.02 | $8.73 | 5.16 |
| 2014-09-30 | 36.33 | $9.10 | 3.99 |
| 2014-06-30 | 41.18 | $8.97 | 4.59 |
| 2014-03-31 | 39.00 | $8.55 | 4.56 |
| 2013-12-31 | 34.66 | $7.97 | 4.35 |
| 2013-09-30 | 30.48 | $8.45 | 3.61 |
| 2013-06-30 | 24.78 | $7.72 | 3.21 |
| 2013-03-31 | 23.13 | $7.58 | 3.05 |
| 2012-12-31 | 21.92 | $8.49 | 2.58 |
| 2012-09-30 | 19.46 | $8.90 | 2.19 |
| 2012-06-30 | 17.07 | $7.88 | 2.16 |
| 2012-03-31 | 18.73 | $8.82 | 2.12 |
| 2011-12-31 | 17.14 | $8.21 | 2.09 |
| 2011-09-30 | 13.57 | $8.19 | 1.66 |
| 2011-06-30 | 19.70 | $9.11 | 2.16 |
| 2011-03-31 | 18.10 | $8.94 | 2.02 |
| 2010-12-31 | 16.87 | $8.29 | 2.04 |
| 2010-09-30 | 15.02 | $11.44 | 1.31 |
| 2010-06-30 | 13.61 | $9.63 | 1.41 |
| 2010-03-31 | 18.14 | $10.30 | 1.76 |
| 2009-12-31 | 14.72 | $10.26 | 1.43 |
| 2009-09-30 | 12.79 | $10.05 | 1.27 |
| 2009-06-30 | 10.42 | $9.54 | 1.09 |
| 2009-03-31 | 10.71 | $8.69 | 1.23 |
| 2008-12-31 | 7.90 | $9.15 | 0.86 |
| 2008-09-30 | 9.12 | $9.78 | 0.93 |
| 2008-06-30 | 9.64 | $10.28 | 0.94 |
| 2008-03-31 | 9.26 | $10.36 | 0.89 |
| 2007-12-31 | 11.23 | $11.18 | 1.00 |
| 2007-09-30 | 12.75 | $7.58 | 1.68 |
| 2007-06-30 | 14.53 | $6.93 | 2.09 |
| 2007-03-31 | 16.83 | $6.64 | 2.54 |
| 2006-12-31 | 15.84 | $5.17 | 3.06 |
| 2006-09-30 | 15.93 | $4.52 | 3.53 |
| 2006-06-30 | 15.78 | $4.13 | 3.82 |
| 2006-03-31 | 18.41 | $3.75 | 4.91 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $19.549B | $14.300B |
| Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $146.474B | 25.66 |
| CVS Health (CVS) | United States | $117.307B | 11.70 |
| HCA Healthcare (HCA) | United States | $93.189B | 14.49 |
| Elevance Health (ELV) | United States | $89.472B | 14.04 |
| Cencora (COR) | United States | $60.778B | 18.57 |
| Natera (NTRA) | United States | $49.779B | 0.00 |
| Labcorp Holdings (LH) | United States | $26.318B | 18.55 |
| Medpace Holdings (MEDP) | United States | $17.206B | 36.13 |
| DiDi Global (DIDIY) | China | $16.502B | 181.00 |
| Revvity (RVTY) | United States | $16.261B | 27.24 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $15.991B | 0.00 |
| Solventum (SOLV) | United States | $15.121B | 12.51 |
| ICON (ICLR) | Ireland | $13.318B | 18.10 |
| Charles River Laboratories (CRL) | United States | $13.052B | 27.62 |
| BrightSpring Health Services (BTSG) | United States | $11.666B | 40.11 |
| Avantor (AVTR) | United States | $10.558B | 19.04 |
| BioMerieux (BMXMF) | France | $9.856B | 0.00 |
| Caris Life Sciences,�Inc (CAI) | United States | $7.972B | 78.36 |
| HealthEquity (HQY) | United States | $7.941B | 25.88 |
| Sonic Healthcare (SKHHY) | Australia | $6.793B | 0.00 |
| PACS (PACS) | United States | $6.761B | 22.72 |
| GETINGE (GNGBY) | Sweden | $6.602B | 18.65 |
| MiniMed (MMED) | United States | $6.302B | 0.00 |
| CochLear (CHEOY) | Australia | $6.298B | 0.00 |
| Bausch + Lomb (BLCO) | Canada | $6.100B | 23.07 |
| Sotera Health (SHC) | United States | $5.516B | 22.74 |
| Concentras Parent (CON) | United States | $4.638B | 22.87 |
| Organon (OGN) | United States | $3.590B | 4.56 |
| GeneDx Holdings (WGS) | United States | $2.905B | 270.61 |
| CareDx (CDNA) | United States | $2.770B | 315.00 |
| Amplifon S.p.A (AMFPF) | Italy | $2.466B | 12.74 |
| Pediatrix Medical (MD) | United States | $2.123B | 12.44 |
| Establishment Labs Holdings (ESTA) | United States | $2.121B | 0.00 |
| Progyny (PGNY) | United States | $2.101B | 29.76 |
| COMPASS Pathways (CMPS) | United Kingdom | $1.911B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $1.895B | 0.00 |
| Surgery Partners (SGRY) | United States | $1.824B | 69.65 |
| Alignment Healthcare (ALHC) | United States | $1.807B | 45.84 |
| Bora Pharmaceuticals, - (BORAY) | Taiwan | $1.692B | 10.16 |
| Freenome (FRNM) | United States | $1.583B | 0.00 |
| Ardent Health (ARDT) | United States | $1.512B | 8.65 |
| Agilon Health (AGL) | United States | $1.506B | 0.00 |
| Nutex Health (NUTX) | United States | $1.488B | 8.53 |
| InnovAge Holding (INNV) | United States | $1.481B | 0.00 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.241B | 0.00 |
| Omada Health (OMDA) | United States | $1.210B | 247.00 |
| Teladoc Health (TDOC) | United States | $1.168B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.161B | 22.60 |
| CryoPort (CYRX) | United States | $0.836B | 0.00 |
| Enhabit (EHAB) | United States | $0.709B | 25.89 |
| GMR Solutions (GMRS) | United States | $0.701B | 0.00 |
| Oncology Institute (TOI) | United States | $0.507B | 0.00 |
| Charming Medical (MCTA) | Hong Kong, SAR China | $0.504B | 0.00 |
| Strata Critical Medical (SRTA) | United States | $0.462B | 0.00 |
| SBC Medicals (SBC) | United States | $0.461B | 9.53 |
| Forward Industries (FWDI) | United States | $0.444B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.387B | 5.62 |
| Shoulder Innovations (SI) | United States | $0.372B | 0.00 |
| Biodesix (BDSX) | United States | $0.301B | 0.00 |
| Embecta (EMBC) | United States | $0.291B | 2.51 |
| So-Young (SY) | China | $0.285B | 0.00 |
| LifeMD (LFMD) | United States | $0.155B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.107B | 0.00 |
| Park Dental Partners (PARK) | United States | $0.097B | 0.00 |
| SkinHealth Systems (SKIN) | United States | $0.088B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.080B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.071B | 8.37 |
| Tevogen (TVGN) | United States | $0.051B | 0.00 |
| DocGo (DCGO) | United States | $0.038B | 0.00 |
| Lifeward (LFWD) | United States | $0.020B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.014B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.013B | 0.00 |
| Ainos (AIMD) | United States | $0.010B | 0.00 |
| XWELL (XWEL) | United States | $0.008B | 0.00 |
| Aclarion (ACON) | United States | $0.007B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.007B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.007B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.007B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.006B | 0.00 |
| Pomdoctor - (POM) | China | $0.006B | 0.00 |
| 20/20 Biolabs (AIDX) | United States | $0.006B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.006B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.004B | 0.00 | |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| Synergy CHC (SNYR) | United States | $0.000B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |